LOS ANGELES, CA--(Marketwired - Oct 5, 2016) - Stellar Biotechnologies, Inc. (NASDAQ: SBOT), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, announced today that Gary Koppenjan has joined the company as Senior Director of Investor Relations and Communications.
Stellar President and CEO Frank Oakes said that the appointment is an important part of Stellar's growth initiative which builds on the company's uplisting to Nasdaq and includes increased stakeholder outreach to support its expansion plans. The company anticipates increased demand for Keyhole Limpet Hemocyanin (KLH) in a wide-range of therapeutic and diagnostic markets. This executive role replaces the company's previous corporate development and communications position.
"Gary's extensive experience in communications, especially his demonstrated success in raising the profile of public companies, will be a valuable asset for Stellar as we reach a broader audience and position Stellar to be the leading KLH company in the field of active immunotherapy," said Mr. Oakes.
Mr. Koppenjan joins Stellar with more than 20 years of experience in corporate communications, marketing and investor relations. Most recently, he led investor relations for a public life science company that was acquired by a large conglomerate. Previously, he held various marketing and communications positions at a global crop science company. During his career, Koppenjan has received multiple advertising and public relations awards for product introduction campaigns and stakeholder outreach. He is a past member of the Biotechnology Industry Organization's communications committee and the California Department of Food and Agriculture's Technical Advisory Committee. Koppenjan is a graduate of the University of California at Los Angeles.
"Stellar is uniquely positioned to impact a wide range of therapeutic pipelines with potentially game-changing treatments of serious diseases, and I'm excited to join the company at this key inflection point in its growth and development. I look forward to extending Stellar's outreach and increasing communications with our stakeholders and investors as well as our customers as they advance through clinical development and prepare for commercial launch," said Mr. Koppenjan.
Follow Stellar: LinkedIn | Twitter | Facebook | Google+
Based north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. (NASDAQ: SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. The company is committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.
Stellar Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; governmental regulations and the ability or failure to comply with governmental regulations; the timing of Stellar's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of Stellar's joint ventures and strategic partnerships; and other factors referenced in the Stellar's filings with securities regulators. For a discussion of further risks and uncertainties related to the Stellar's business, please refer to the Stellar's public company reports filed with the U.S. Securities and Exchange Commission and the B.C. Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Stellar assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.